A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Fosrenol
Synonyms :
lanthanum carbonate
Class :
Phosphate binders
Brand Name :
Fosrenol
Synonyms :
lanthanum carbonate
Class :
Phosphate binders
Dosage Forms & StrengthsÂ
Chewable TabletÂ
1000mgÂ
750mgÂ
500mg Â
Oral PowderÂ
1000mgÂ
750mgÂ
End Stage Renal Disease (ESRD)Â
in patients with Serum Phosphate Reduction
:
Initially, use 750-1500 mg/day orally in split doses.
Once a desired serum phosphate level is attained, titrate in increments of 750 mg once every two to three weeks.
most patients needed a total daily dosage of between 1500 and 3000 mg to lower plasma phosphate levels to 6.0 mg/dL
Not recommendedÂ
Refer to adult dosing regimenÂ
lanthanum may decrease the serum concentration of quinolones
lanthanum may decrease the serum concentration of quinolones
may diminish the serum concentration when combined with ampicillin
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the therapeutic effect when combined with lanthanum
may diminish the therapeutic effect when combined with lanthanum
may diminish the therapeutic effect when combined with lanthanum
may diminish the therapeutic effect when combined with lanthanum
may diminish the therapeutic effect when combined with lanthanum
may diminish the serum concentration when combined with bacampicillin
may diminish the serum concentration when combined with chloroquine
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
may diminish the serum concentration when combined with HMG-CoA reductase inhibitors (statins)
may diminish the serum concentration when combined with quinolones
may diminish the serum concentration when combined with quinolones
bismuth subcitrate, metronidazole and tetracycline
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with tetracyclines
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
lanthanum carbonate: they may decrease the therapeutic effect of antacids
lanthanum carbonate: they may decrease the therapeutic effect of antacids
phosphate binders: they may diminish the serum concentration of antacids
phosphate binders: they may diminish the serum concentration of antacids
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the serum concentration when combined with halofantrine
may diminish the serum concentration of magnesium salts
may have a decreased serum concentration when combined with phosphate supplements
may have a decreased serum concentration when combined with phosphate supplements
may have a decreased serum concentration when combined with phosphate supplements
may have a decreased serum concentration when combined with phosphate supplements
may have a decreased serum concentration when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
calcium salts: they may diminish the absorption of phosphate binders
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may diminish the serum concentration when combined with phosphate supplements
may diminish the absorption when combined with phosphate supplements
may diminish the serum concentration of magnesium salts
may decrease the serum concentration when combined
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may decrease the effects of the drug by GI absorption inhibition
may diminish the serum concentration when combined with thyroid products
may diminish the serum concentration when combined with thyroid products
may diminish the serum concentration when combined with thyroid products
may diminish the serum concentration when combined with thyroid products
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
It may enhance the risk of adverse effects when combined with phosphate binders
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
may have an increased nephrotoxic effect when combined with NSAIDs
Decreases the ampicillin serum concentrations.
it reduces the therapeutic effects of demeclocycline by inhibiting GI absorption
it reduces the therapeutic effects of doxycycline by inhibiting GI absorption
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increasingly adverse effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
spironolactone and hydrochlorothiazide
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
may have an increased nephrotoxic effect when combined with sodium phosphates
Actions and spectrum:Â
lanthanum carbonate is a medication used to treat high levels of phosphate in the blood in patients with end-stage kidney disease. It acts by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption and promoting its elimination from the body.
By reducing the amount of phosphate in the blood, it helps to prevent complications such as bone disease, heart disease, and other problems associated with high phosphate levels in the body.Â
lanthanum carbonate is classified as a phosphate binder and works by chelating the phosphate ions present in the gastrointestinal tract, forming an insoluble complex that is then excreted in the feces.Â
Frequency defined:Â Â
1-10%Â
Abdominal painÂ
Dialysis graft complication/occlusionÂ
HeadacheÂ
NauseaÂ
ConstipationÂ
DiarrheaÂ
Vomiting Â
<1%Â
BronchitisÂ
RhinitisÂ
Hypercalcemia Â
Post marketing ReportsÂ
DyspepsiaÂ
HypophosphatemiaÂ
Tooth injuryÂ
Intestinal obstructionÂ
Sub ileusÂ
Allergic skin reactionsÂ
HypocalcemiaÂ
Intestinal perforationÂ
IleusÂ
Contraindication/Caution:Â
ContraindicationÂ
lanthanum carbonate is contraindicated in individuals with a known hypersensitivity to lanthanum or any of the excipients used in the formulation. It is also contraindicated in individuals with bowel obstruction, ileus, or fecal impaction. Â
CautionÂ
ComorbiditiesÂ
Pregnancy consideration: pregnancy category CÂ
Lactation: safety and efficacy not established Â
Pregnancy category:Â
Pharmacology:Â
lanthanum carbonate is a phosphate binder used to treat hyperphosphatemia in patients with end-stage renal disease. When taken orally, it binds to dietary phosphate in the GI tract, forming an insoluble complex that is excreted in the feces. lanthanum carbonate does not enter the systemic circulation and therefore does not affect calcium, vitamin D, or other minerals in the body. Â
Pharmacodynamics:Â
lanthanum carbonate is a phosphate binder that lowers serum phosphate concentrations by binding to dietary phosphate in the gastrointestinal tract and forming an insoluble complex, which is excreted in the feces. The pharmacodynamics of lanthanum carbonate are based on its ability to bind to phosphate ions in the gastrointestinal tract, leading to reduced phosphate absorption and a subsequent decrease in serum phosphate levels. Â
Pharmacokinetics:Â
lanthanum carbonate is not absorbed systemically after oral administration and acts locally in the gastrointestinal tract. After oral ingestion, it binds to dietary phosphate in the lumen of the gastrointestinal tract, forming an insoluble complex that is excreted in the feces. The absorbed lanthanum is eliminated primarily by the hepatobiliary system and excreted in the feces. No significant metabolism of lanthanum carbonate occurs.Â
Administration:Â
lanthanum carbonate is available in tablet form for oral administration. The tablets should be taken with food and not be chewed, crushed, or broken. The dosage may be adjusted based on serum phosphorus levels and should be taken with caution.Â
Patient information leafletÂ
Generic Name: lanthanum carbonateÂ
Pronounced: [ lan-than-um-car-bo-nayt ]Â Â
Why do we use lanthanum carbonate?lanthanum carbonate is used in patients with end-stage renal disease to treat hyperphosphatemia who are undergoing dialysis. It works by binding to phosphate in the gastrointestinal tract, preventing its absorption into the body and therefore reducing the amount of phosphate in the blood.
This can help to prevent complications such as bone disease, calcification of soft tissues, and cardiovascular disease that can occur because of elevated levels of phosphate in the blood.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
